Not 100% comparing apples with apples, but it does appear ciltacabtagene autoleucel (cilta-cel), will over time become 1st line treatment, where its currently on 3rd line treatment.
https://www.cancernetwork.com/view/adjusted-comparison-of-cilta-cel-vs-standard-regimens-reveals-favorable-outcomes-in-triple-class-exposed-multiple-myeloma
Ann: Expanded Heart Protection Discovery for Zantrene, page-257
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
-0.010(0.66%) |
Mkt cap ! $260.0M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.57 | $1.51 | $72.91K | 47.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 461 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 1047 | 1 |
View Market Depth
| Last trade - 11.13am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.53 | $1.56 | $1.51 | 3079 | ||
| Last updated 11.13am 22/05/2024 ? | |||||
| RAC (ASX) Chart |